ENvue Medical Secures $1 Million Debt Agreement and Lowers Preferred Stock Conversion Price
ENvue Medical, Inc. (OTC:FEED) has taken two financial steps to strengthen its cash position and prepare for future fundraising. The company entered into a secured promissory note with Alpha Capital Anstalt for up to $1 million, receiving an initial $250,000 funding tranche. The loan carries a 10% annual interest rate, is backed by substantially all company assets, and matures on Dec. 31, 2026, with options to extend quarterly through 2028.
Alongside the new debt, ENvue amended its Series X Preferred Stock terms to reduce the conversion price to $0.50 per share and revise anti-dilution terms. Management implemented these changes to align investor terms and give the business greater financial flexibility while funding ongoing operations. Following the disclosure, shares of ENvue Medical dropped 7.27% to close at $0.51.
Investors will be watching whether ENvue Medical draws the remaining $750,000 available under the debt agreement and if the updated preferred stock terms help the company successfully secure additional equity financing in the coming months.
Key points
- ENvue Medical entered a secured note agreement with Alpha Capital Anstalt for up to $1 million at 10% interest, with $250,000 funded initially.
- The loan is backed by substantially all company assets and matures on Dec. 31, 2026, with potential quarterly extensions through 2028.
- The company lowered the conversion price of its Series X Preferred Stock to $0.50 per share and modified anti-dilution provisions.
- Shares of ENvue Medical fell 7.27% to $0.51 following the disclosure.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What financing did ENvue Medical recently secure?
ENvue Medical signed a secured promissory note with Alpha Capital Anstalt for up to $1 million at 10% interest, backed by substantially all company assets. The company received an initial $250,000 tranche.
How did ENvue Medical change its Series X Preferred Stock terms?
ENvue Medical amended its Series X Preferred Stock terms to reduce the conversion price to $0.50 per share and update anti-dilution provisions to support future equity capital raising.
When does ENvue Medical's new promissory note mature?
The debt agreement matures on Dec. 31, 2026, but can be extended quarterly up to Dec. 31, 2028.